Patent Defenses Addressed On The Merits Even After Non-Infringement Finding Affirmed
Client Alert | 1 min read | 05.22.06
In Old Town Canoe Co. v. Confluence Holdings Corp . (May 9, 2006; Nos. 05-1123, 05-1148), a Federal Circuit panel affirms findings of non-infringement and no inequitable conduct based on motions for judgment as a matter of law ("JMOL"), but vacates JMOL findings of no invalidity and remands for further proceedings. The patent-in-suit claims a method for making a laminated plastic boat hull by rotational molding, and the parties disputed whether, in the accused process, "coalescence" was "completed." In finding non-infringement, the Federal Circuit affirms the district court's claim construction and agrees that the disputed limitation requires the plastic laminate to reach the end of coalescence, that is, its optimum state as disclosed in one of the patent diagrams. Because the accused process is "brought to a halt," it does not infringe.
With respect to invalidity, the Federal Circuit concludes that the accused infringer presented enough evidence that a reasonable juror could decide against the patentee on each of the obviousness, enablement, and best mode defenses, and thus vacates the JMOL. In contrast, patentee did not provide enough evidence for the Federal Circuit to conclude that the district court abused its discretion in finding no inequitable conduct, and thus JMOL of no inequitable conduct is affirmed.
While agreeing with the JMOL of non-infringement, Judge Mayer dissents from the panel's resolution of the invalidity and unenforceability counterclaims as lacking an actual controversy.
Insights
Client Alert | 7 min read | 09.14.26
AI in Life Sciences: Ten Legal Considerations and Risks of AI Use in Drug Discovery and Development
Over the past several years, the biopharmaceutical industry has embraced artificial intelligence and machine learning (AI/ML) in near lockstep with the pace of AI/ML innovations. Today, industry leaders are using AI/ML to, among other things: discover and assess biological pathways, target chemical structures and sequences; design proteins; model pre-clinical and clinical trials; recruit and screen potential patient populations; evaluate clinical trial results and biomarker data; prepare regulatory filings; and manage supply chains. Deployment of new AI/ML models promises extraordinary advances in pharmaceutical development. However, as with any technological and scientific advances, the use of AI/ML also poses substantial legal risks that life sciences companies need to consider and proactively manage.
Client Alert | 6 min read | 09.14.26
Mental Health Parity Bulletin Restates Best Practices for Evaluating Compliance
Client Alert | 6 min read | 09.11.26
It’s LIVE: The Cyber Resilience Act Reporting Is Mandatory as of Today - 11 September 2026
Client Alert | 10 min read | 09.11.26
Mining, Indigenous Consultation Rights, and Investment Treaty Protection
